Redx Pharma plc Hardman Research: Streamlined and clean
November 13 2017 - 1:15AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
13 November 2017
Hardman Research: Streamlined and clean
Streamlined and clean - Redx has emerged from administration
with a refocused R&D pipeline and in a very clean financial
state with GBP13.6m net cash in the bank. The group's strategy has
been validated by the successful disposal of its pre-clinical
programme BTK for $40m. The new Board & Management team will
focus resources on the early clinical development of its next two
lead candidates, in oncology and fibrotic disease, which are
expected to start Phase I trials in 2018 and 2019, respectively.
There was an inevitable knee-jerk reaction when the shares were
re-quoted but consideration should be given to the potential value
within the focused pipeline.
Please click here for the full report:
http://hardmanandco.com/docs/default-source/company-docs/redx-pharma--documents/13.11.17-streamlined-and-clean.pdf
To contact us: Contacts: mh@hardmanandco.com
Hardman & Co Dr Martin dmh@hardmanandco.com
35 New Broad Street Hall gp@hardmanandco.com
London Dr Dorothea hardman@hardmanandco.com
EC2M 1NH Hill
Follow us on Twitter Dr Gregoire
@HardmanandCo Pave
+44 20 7194
7622
About Hardman & Co: For the past 20 years Hardman has been
producing specialist research designed to improve investors'
understanding of companies, sectors, industries and investment
securities. Our analysts are highly experienced in their sectors,
and have often been highly rated by professional investors for
their knowledge. Our focus is to raise companies' profiles across
the UK and abroad with outstanding research, investor engagement
programmes and advisory services. Some of our notes have been
commissioned by the company which is the subject of the note; this
is clearly stated in the disclaimer where this is the case.
Hardman Research Ltd, trading as Hardman & Co, is an
appointed representative of Capital Markets Strategy Ltd and is
authorised and regulated by the Financial Conduct Authority; our
FCA registration number is 600843. Hardman Research Ltd is
registered at Companies House with number 8256259.
Our research is provided for the use of the professional
investment community, market counterparties and sophisticated and
high net worth investors as defined in the rules of the regulatory
bodies. It is not intended to be made available to unsophisticated
retail investors. Anyone who is unsure of their categorisation
should consult their professional advisors. This research is
neither an offer, nor a solicitation, to buy or sell any security.
Please read the note for the full disclaimer.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFVRLRLILID
(END) Dow Jones Newswires
November 13, 2017 02:15 ET (07:15 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024